

---

# 1<sup>st</sup> Workshop “Modelling Immuno-Oncology”

## March 30th, 2023 (online event, UTC/GMT +1 hour)

### Scientific Program

---

- 10:30 -11:00 **Welcome and Opening: IMMUNO-model – what it is about**  
Prof. Johannes Haybaeck, MD, PhD *Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Austria*
- 11:00-11:20 **Treg-targeted therapies for immuno-oncology using humanized mice**  
Gilles Marodon *CIMI-PARIS, Sorbonne University, INSERM, CNRS*
- 11:30-11:50 **Mouse models used to study the adoptive cell therapy to treat tumors**  
Roberta Sommaggio *Department of Surgery Oncology and Gastroenterology University of Padova, Italy and Veneto Institute of Oncology IOV-IRCCS*
- 12:00-12:20 **Gain or loss of function in the STAT5A or STAT5B pathways and consequences for immunity or T-cell cancer initiation and progression**  
Rickard Moriggl *Ludwig Boltzmann Institute for Cancer Research and Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna*
- 12:30-12:50 **Patient-derived cell culture models in translational oncology**  
Christian Regenbrecht *CELLphenomics GmbH*
- 13:00-13:45 **Lunch**
- 13:45-14:05 **Tailoring nanocarrier delivery-targets with Chemokines**  
Giuseppe Bardi *NanoBioInteractions & Nanodiagnosics - Istituto Italiano di Tecnologia (Genova, Italy)*
- 14:15-14:35 **Advanced ovarian cancer models for immunotherapy applications – key aspects, major drawbacks, and future perspectives**  
Katrin Kleinmanns *Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen*
- 14:45-15:05 **Modeling the tumor microenvironment heterogeneity and immune vascular cross-talks in ex-vivo microphysiological models**  
Marco Campisi *Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, MA, US*
- 15:15-15:35 **Pet dogs as translational patient models for cancer immunotherapy development**  
Amy LeBlanc *Senior Scientist and Director, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health*
- 15:45-16:05 **TBA**  
Michael Brehm *Diabetes Center of Excellence, Program in Molecular Medicine University of Massachusetts Chan Medical School*
- 16:15-16:30 Closing remarks